Cargando…

CDK4/6 inhibition protects normal cells against cancer therapy-induced damage

Detalles Bibliográficos
Autores principales:	Boopathi, Ettickan, Thangavel, Chellappagounder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236812/ https://www.ncbi.nlm.nih.gov/pubmed/32432028 http://dx.doi.org/10.21037/tcr.2019.12.86

Ejemplares similares

Dark Side of Cancer Therapy: Cancer Treatment-Induced Cardiopulmonary Inflammation, Fibrosis, and Immune Modulation
por: Boopathi, Ettickan, et al.
Publicado: (2021)

Innate Immune System in the Context of Radiation Therapy for Cancer
por: Boopathi, Ettickan, et al.
Publicado: (2023)

Bone Health Management in the Continuum of Prostate Cancer Disease
por: Boopathi, Ettickan, et al.
Publicado: (2022)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan
por: Blume, Joshua, et al.
Publicado: (2023)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

Oxygen-independent, CDK4/CDK6-dependent degradation of hypoxia-inducible factor-1α takes cancers’ breath away
por: Neckers, Len
Publicado: (2022)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?
por: Becher, Oren J.
Publicado: (2019)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

A dual role of Cdk2 in DNA damage response
por: Satyanarayana, Ande, et al.
Publicado: (2009)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

Efficient Wnt mediated intestinal hyperproliferation requires the cyclin D2-CDK4/6 complex
por: Myant, Kevin, et al.
Publicado: (2011)

CDK4/6 inhibition is more active against the glioblastoma proneural subtype
por: Li, Ming, et al.
Publicado: (2017)

Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.
por: Kovatcheva, Marta, et al.
Publicado: (2017)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

CDK4, a new metabolic sensor that antagonizes AMPK
por: Fajas, L., et al.
Publicado: (2018)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
por: Purba, Talveen S, et al.
Publicado: (2019)

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
por: Akhade, Amol, et al.
Publicado: (2022)

Targeting CDK4/6 for Anticancer Therapy
por: Qi, Jiating, et al.
Publicado: (2022)

CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia-induced damage
por: Liu, Guanghui, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

CDK4, pRB and E2F1: connected to insulin
por: Fajas, Lluis, et al.
Publicado: (2010)

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
por: van Leeuwen, Ingeborg M.M., et al.
Publicado: (2011)

Targeting p27 tyrosine phosphorylation as a modality to inhibit CDK4 and CDK2 and cause cell cycle arrest in breast cancer cells
por: Blain, Stacy W.
Publicado: (2018)

Silencing CDK6-AS1 inhibits LPS-induced inflammatory damage in HK-2 cells
por: Wu, Ling, et al.
Publicado: (2021)

Blocking cell cycle progression through CDK4/6 protects against chronic kidney disease
por: Osaki, Yosuke, et al.
Publicado: (2022)

Therapeutic potential of CDK11 in cancer
por: Blazek, Dalibor
Publicado: (2023)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

CDK4/6 inhibition triggers anti-tumor immunity
por: Goel, Shom, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hof99dmkvrq1vi1osbni1u7psj